CO5721011A2 - Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos - Google Patents

Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos

Info

Publication number
CO5721011A2
CO5721011A2 CO05023614A CO05023614A CO5721011A2 CO 5721011 A2 CO5721011 A2 CO 5721011A2 CO 05023614 A CO05023614 A CO 05023614A CO 05023614 A CO05023614 A CO 05023614A CO 5721011 A2 CO5721011 A2 CO 5721011A2
Authority
CO
Colombia
Prior art keywords
nucleic acid
cell
estrogen receptor
vector
host cell
Prior art date
Application number
CO05023614A
Other languages
English (en)
Inventor
Peter Van Nest Bodine
Dan Gazit
Original Assignee
Wyeth Corp
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Yissum Res Dev Co filed Critical Wyeth Corp
Publication of CO5721011A2 publication Critical patent/CO5721011A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1.- Una molécula de acido nucleico aislada que comprende un acido nucleico, que corresponde a una region reguladora BMP-2, caracterizada porque comprende un elemento sensible al estrogeno.2.- Un vector que comprende el acido nucleico de conformidad con la reivindicacion 1, caracterizado porque el acido nucleico se enlaza operativamente a un segundo acido nucleico.3.- Una célula hospedadora caracterizada porque comprende el vector de conformidad con la reivindicacion 2.4.- La célula hospedadora de conformidad con la reivindicacion 3, caracterizada porque la célula comprende ademas un receptor de estrogeno.5.- La célula hospedadora de conformidad con la reivindicacion 4, caracterizada porque el receptor de estrogeno es a.6.- La célula hospedadora de conformidad con la reivindicacion 4, caracterizada porque el receptor de estrogeno es ß.7.- Un método para la identificacion de un agente terapéutico para la prevencion y/o tratamiento de la osteoporosis, caracterizado porque comprende:(a) introducir en una célula el vector de conformidad con la reivindicacion 2, (b) poner en contacto la célula con un agente candidato;y (c) monitorear la expresion de la proteina codificada por el acido nucleico reportero, en donde la expresion inducida de la proteina indica que el agente candidato es un agente terapéutico potencial.8.- El método de conformidad con la reivindicacion 7, caracterizado porque en la etapa (a) un segundo vector de expresion que comprende una molécula de acido nucleico que codifica a un receptor de estrogeno se introduce en la célula.9.- El método de conformidad con la reivindicacion 8, caracterizado porque el receptor de estrogeno es a.
CO05023614A 2002-08-16 2005-03-14 Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos CO5721011A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40402402P 2002-08-16 2002-08-16

Publications (1)

Publication Number Publication Date
CO5721011A2 true CO5721011A2 (es) 2007-01-31

Family

ID=31888312

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05023614A CO5721011A2 (es) 2002-08-16 2005-03-14 Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos

Country Status (14)

Country Link
US (1) US20050271637A1 (es)
EP (1) EP1534731A4 (es)
JP (1) JP2006500925A (es)
KR (1) KR20050083635A (es)
CN (1) CN1753904A (es)
AU (1) AU2003261246A1 (es)
BR (1) BR0313729A (es)
CA (1) CA2497304A1 (es)
CO (1) CO5721011A2 (es)
MX (1) MXPA05001694A (es)
NO (1) NO20050935L (es)
RU (1) RU2005107330A (es)
WO (1) WO2004016639A1 (es)
ZA (1) ZA200502131B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (en) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI480048B (zh) 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES2575695T3 (es) 2009-03-30 2016-06-30 Acceleron Pharma Inc. Antagonistas de BMP-ALK3 y sus usos para estimular el crecimiento óseo
EP3345921A1 (en) 2009-06-08 2018-07-11 Acceleron Pharma Inc. Use of anti-actriib antibodies for increasing thermogenic adipocytes
ES2836534T3 (es) 2009-06-12 2021-06-25 Acceleron Pharma Inc Proteínas de fusión de ActRIIB-Fc truncadas
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
US8501690B2 (en) 2010-04-30 2013-08-06 John G. Stark Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
CN104936605A (zh) 2012-11-02 2015-09-23 细胞基因公司 激活素-actrii拮抗剂和用于治疗骨和其它病症的用途
WO2015192111A1 (en) 2014-06-13 2015-12-17 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
KR102556991B1 (ko) 2014-12-03 2023-07-19 셀진 코포레이션 액티빈-ActRII 길항제 및 빈혈 치료를 위한 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
JPS59500735A (ja) * 1983-04-18 1984-04-26 エス・ア−ル・アイ・インタ−ナシヨナル 人間の癌診断のための方法および試験キツト
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
WO1998025460A1 (en) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions and methods for stimulating bone growth
JPH11313673A (ja) * 1998-04-30 1999-11-16 Hoechst Marion Roussel Kk ヒトｂｍｐ−２プロモーターおよびこれを用いた骨関連物質の探索法
US6630304B1 (en) * 2000-09-14 2003-10-07 Decode Genetics Ehf. Human osteoporosis gene

Also Published As

Publication number Publication date
JP2006500925A (ja) 2006-01-12
EP1534731A1 (en) 2005-06-01
MXPA05001694A (es) 2005-07-22
CA2497304A1 (en) 2004-02-26
EP1534731A4 (en) 2006-05-17
CN1753904A (zh) 2006-03-29
NO20050935L (no) 2005-05-10
KR20050083635A (ko) 2005-08-26
AU2003261246A1 (en) 2004-03-03
WO2004016639A1 (en) 2004-02-26
ZA200502131B (en) 2005-09-21
BR0313729A (pt) 2005-06-21
US20050271637A1 (en) 2005-12-08
RU2005107330A (ru) 2005-10-10

Similar Documents

Publication Publication Date Title
CO5721011A2 (es) Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos
BR0200282A (pt) Sistema e método para determinar exigências especìficas a partir de documentos de exigências gerais
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
WO2002031134A3 (en) Novel serine protease genes related to dppiv
BR0016569A (pt) Processo de isolamento de rna de espécimes de tecido embutidos - parafina fixados - formalina
ATE298890T1 (de) Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
CY1109207T1 (el) Διαδικασια εχινοκανδινης
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
BR0000068A (pt) Sistema e método para iniciar a operação de um sistema de computador
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
IT1261847B (it) Metodo per marcare cellule eucariote.
Posner et al. AURINTRICARBOXYLIC ACm IS AN INHIBITOR OF 11-AND m-CALPAIN
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
HUP0203957A2 (hu) Az érképződést és az érrendszeri permeabilitást módosító és gátló hatóanyagok
DE69031271D1 (de) Varianten von pai-2
BR0210905A (pt) Anticorpos especìficos para cd44v6
ATE495255T1 (de) Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
WO2005006949A3 (en) Methods for predicting development of auto-immune diseases and treatment of same
DE602005014542D1 (de) Kosmetische zusammensetzung zum abnehmen mit einem metalloproteinase-hemmer als wirkstoff
BR0312274A (pt) polipeptìdeos imunogênicos de mycoplasma hyopneumoniae
SE0301987D0 (sv) New polypeptide
ATE364689T1 (de) Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
Rosenberg et al. The action of chymotrypsin on nucleosome cores. Histone products and conformational effects of limited digestion.
BR0213756A (pt) Sistema e método para configurar remotamente um rádio, e, estrutura de dados em um perfil de usuário localizado em um banco de dados
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata

Legal Events

Date Code Title Description
FA Application withdrawn